These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 22291914)

  • 21. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
    Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary metabolomic signature of esophageal cancer and Barrett's esophagus.
    Davis VW; Schiller DE; Eurich D; Sawyer MB
    World J Surg Oncol; 2012 Dec; 10():271. PubMed ID: 23241138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SOX2 as a novel marker to predict neoplastic progression in Barrett's esophagus.
    van Olphen S; Biermann K; Spaander MC; Kastelein F; Steyerberg EW; Stoop HA; Bruno MJ; Looijenga LH
    Am J Gastroenterol; 2015 Oct; 110(10):1420-8. PubMed ID: 26323187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer: A Phase III Study.
    Maddalo G; Fassan M; Cardin R; Piciocchi M; Marafatto F; Rugge M; Zaninotto G; Pozzan C; Castoro C; Ruol A; Biasiolo A; Farinati F
    J Clin Gastroenterol; 2018; 52(5):401-406. PubMed ID: 28422774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Biomarkers for Human Papillomavirus With Survival Among Adults With Barrett High-grade Dysplasia and Esophageal Adenocarcinoma.
    Rajendra S; Sharma P; Gautam SD; Saxena M; Kapur A; Sharma P; Merrett N; Yang T; Santos LD; Pavey D; Sharaiha O; McKay O; Dixson H; Xuan W
    JAMA Netw Open; 2020 Feb; 3(2):e1921189. PubMed ID: 32058552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic correlation between the expression of the DNA repair enzyme N-methylpurine DNA glycosylase and esophageal adenocarcinoma onset: a retrospective pilot study.
    Zaïr ZM; Johnson GE; Griffiths AP; Jenkins GJ
    Dis Esophagus; 2013 Aug; 26(6):644-50. PubMed ID: 23137018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett's Esophagus.
    Mallick R; Patnaik SK; Wani S; Bansal A
    Dig Dis Sci; 2016 Apr; 61(4):1039-50. PubMed ID: 26572780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus.
    Lv J; Guo L; Wang JH; Yan YZ; Zhang J; Wang YY; Yu Y; Huang YF; Zhao HP
    World J Gastroenterol; 2019 Jan; 25(2):233-244. PubMed ID: 30670912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus.
    Bird-Lieberman EL; Dunn JM; Coleman HG; Lao-Sirieix P; Oukrif D; Moore CE; Varghese S; Johnston BT; Arthur K; McManus DT; Novelli MR; O'Donovan M; Cardwell CR; Lovat LB; Murray LJ; Fitzgerald RC
    Gastroenterology; 2012 Oct; 143(4):927-35.e3. PubMed ID: 22771507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus.
    Critchley-Thorne RJ; Duits LC; Prichard JW; Davison JM; Jobe BA; Campbell BB; Zhang Y; Repa KA; Reese LM; Li J; Diehl DL; Jhala NC; Ginsberg G; DeMarshall M; Foxwell T; Zaidi AH; Lansing Taylor D; Rustgi AK; Bergman JJ; Falk GW
    Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):958-68. PubMed ID: 27197290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling.
    Sanchez-Espiridion B; Liang D; Ajani JA; Liang S; Ye Y; Hildebrandt MA; Gu J; Wu X
    Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1730-1737.e9. PubMed ID: 25998788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.
    Dvorak K; Watts GS; Ramsey L; Holubec H; Payne CM; Bernstein C; Jenkins GJ; Sampliner RE; Prasad A; Garewal HS; Bernstein H
    Am J Gastroenterol; 2009 Feb; 104(2):302-9. PubMed ID: 19174784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IMP3 Immunoreactivity is More Sensitive Than AMACR in Detecting Dysplastic Epithelium and Early Adenocarcinoma in Barrett Esophagus.
    Gadara MR; Gonzalez M; Cartun RW; Ligato S
    Appl Immunohistochem Mol Morphol; 2017 Jul; 25(6):386-391. PubMed ID: 26766126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.
    Nancarrow DJ; Clouston AD; Smithers BM; Gotley DC; Drew PA; Watson DI; Tyagi S; Hayward NK; Whiteman DC; ;
    PLoS One; 2011; 6(7):e22513. PubMed ID: 21829465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prior tonsillectomy is associated with an increased risk of esophageal adenocarcinoma.
    Garman KS; Ajayi TA; Boutte HJ; Chiu ST; von Furstenberg RJ; Lloyd BR; Zhang C; Onaitis MW; Chow SC; McCall SJ
    PLoS One; 2020; 15(7):e0235906. PubMed ID: 32697782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
    Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
    Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. D-mannose: a novel prognostic biomarker for patients with esophageal adenocarcinoma.
    Gu J; Liang D; Pierzynski JA; Zheng L; Ye Y; Zhang J; Ajani JA; Wu X
    Carcinogenesis; 2017 Feb; 38(2):162-167. PubMed ID: 28062409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.